Design and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.

Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.

Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.

The effectiveness of four translation strategies on nurses' adoption of an evidence-based bladder protocol.

The primary purpose of this study was to examine the effects of an intervention consisting of the four translation strategies of educational materials, educational meetings, reminders, and audit and feedback on nurses' adoption of an evidence-based bladder program for patients with stroke in an acute care setting. The secondary purpose was to evaluate the difference in incontinence episodes of patients with stroke before and after nurses received the intervention. Finally, the purpose was to evaluate the influence of nurses' attitudes and the demographic characteristics on the adoption and use of the evidence-based bladder program after receiving the intervention.